Cerus Corporation (Nasdaq: CERS) announced today that the U.S.
Department of the Navy will implement pathogen-reduction for all
apheresis platelets collected at Navy Blood Donor Centers.
The Bureau of Medicine and Surgery (BUMED) noted that with the recent
history with Zika Virus, Ebola, Chikungunya, Dengue, and Babesia,
emerging pathogens continue to threaten the blood supply and that the
use of pathogen reduction technologies will preemptively address the
risk due to emerging pathogens.
All Navy Blood Donor Centers are required to implement the policy to
pathogen-reduce platelet components by December 31, 2018.
“We are pleased that the U.S. Navy is expanding the use of
pathogen-reduction technology to treat platelet components throughout
its entire blood collection system,” said William ‘Obi’ Greenman, Cerus’
president and chief executive officer. “By fully adopting pathogen
reduction, the U.S Navy Blood Program is providing our Nation’s Sailors,
Marines, and their families around the globe access to platelets with
reduced risk of transfusion transmitted infection (TTI) from known and
Cerus’ INTERCEPT Blood Systems is currently the only FDA approved
pathogen reduction system commercially available in the U.S. to treat
platelets and is in routine use at the Navy Blood Donor Center at Walter
Reed National Military Medical Center in Bethesda, Maryland.
The U.S. Navy Blood Program operates seven FDA licensed blood collection
centers around the globe to provide quality blood product services for
service members, veterans, and their families. The U.S. Navy Blood
Program is part of BUMED which manages health care activities for the
U.S. Navy and Marine Corps.
The BUMED instruction can be viewed at https://www.med.navy.mil/directives/ExternalDirectives/6530.16.pdf.
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005241/en/